Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

55.14 +13.54 (+32.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merus N.V. - Common Shares

< Previous 1 2 3 Next >
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
From Merus N.V.
Via GlobeNewswire
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCC 
From Merus N.V.
Via GlobeNewswire
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
From Merus N.V.
Via GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback 
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
From Merus N.V.
Via GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
From Merus N.V.
Via GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.